Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide

Protein Replacement Therapy and Gene Transfer in Canine Models of Hemophilia A, Hemophilia B, von Willebrand Disease, and Factor VII Deficiency

(2013) T. C. Nichols et al.   ILAR JOURNAL

Prolonged activity of factor IX as a monomeric Fc fusion protein

(2010) R. T. Peters et al.   BLOOD

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment

(2010) B. Mei et al.   BLOOD

Functional characteristics of N8, a new recombinant FVIII

(2010) M. L. S. CHRISTIANSEN et al.   HAEMOPHILIA

γ-Carboxyglutamic acids 36 and 40 do not contribute to human factor IX function

(2010) Shmuel Gillis et al.   PROTEIN SCIENCE

Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven®) therapy in haemophilia a patients

(2010) Dorthe Viuff et al.   THROMBOSIS RESEARCH

A ferric chloride induced arterial injury model used as haemostatic effect model

(2009) F. MØLLER et al.   HAEMOPHILIA

Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV

(2009) T. GUI et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

(2008) J Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

The Pharmacology of PEGylation: Balancing PD with PK to Generate Novel Therapeutics

(2008) C.Simone Fishburn   JOURNAL OF PHARMACEUTICAL SCIENCES